Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 12, 2004, Pages 1614-1620

  Brink, I ^a   Schumacher, T ^b   Mix, M ^a   Ruhland, S ^a   Stoelben, E ^a   Digel, W ^a   Henke, M ^a   Ghanem, N ^a   Moser, E ^a   Nitzsche, E U ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Diakonie Clinic Freiburg   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

18F FDG PET; Primary staging; Radionuclide imaging; Small cell lung cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG METASTASIS; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; POSITRON EMISSION TOMOGRAPHY; TREATMENT PLANNING; BRAIN TUMOR; HOSPITALIZATION; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY; SCINTISCANNING; SECRETION; SENSITIVITY AND SPECIFICITY; SMALL CELL CARCINOMA;

BRAIN NEOPLASMS; CARCINOMA, SMALL CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 19944428215     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1606-x     Document Type: Article

References (33)

1. Jemal A, Taylor Murray AS, Ghafoor A, Ward E, Thun MJ. Cancer statistics. CA Cancer J Clin 2003;53:5-26.
2. Payne D, Naruke T. Lung cancer. In: Pollock RE, ed. Manual of clinical oncology, 7th edn. New York: Wiley; 1999:385-405.
3. Pasemans M, Sculier JP, Lecombe J, et al. Prognostic factors for patients with small cell lung carcinoma. Cancer 2000; 89:523-33.
4. Simon GR, Wagner H. Small cell lung cancer. Chest 2003; 123(Suppl):259S-271S.
5. Szczesny TJ, Szczesny A, Shepherd FA, et al. Surgical treatment of small cell lung cancer. Semin Oncol 2003;30:47-56.
6. Mountain CF. Revision in the international system for staging lung cancer. Chest 1997;111:1710-7.
7. Richardson GE, Daniel CI. Staging of small cell lung cancer. In: Carney DN, ed. Lung cancer. London: Arnold; 1995: 114-21.
8. Darling GE. Staging of the patient with small cell lung cancer. Chest Surg Clin North Am 1997;7:81-94.
9. Warburg O, Posener K, Negelein E VIII. The metabolism of cancer cells. Biochem Zool 1924;152:129-69.
10. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. J Am Med Assoc 2001;285:914-24.
11. Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - meta-analytic comparison of PET and CT. Radiology 1999;213:530-6.
12. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999;212:803-9.
13. Pieterman RM, Van Putten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small cell lung cancer with positron emission tomography. N Engl J Med 2000;393:254-61.
14. Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998;83:918-24.
15. Schumacher T, Brink I, Mix M, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001;28:483-8.
16. 18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 2003;30:78-84.
17. 18F-fluorodeoxyglucose positron emission tomography in small cell lung cancer. Semin Nucl Med 2002;32:272-5.
18. Hauber HP, Bohuslavizki KH, Lund CH, et al. Positron emission tomography in the staging of small cell lung cancer - a preliminary study. Chest 2001;119:950-4.
19. Chin R, McCain TW, Miller AA, et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 2002;37:1-6.
20. 18F-2- deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res 2002;22:1257-64.
21. 18F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003;44:1911-7.
22. 18F]-fluoro-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-8.
23. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1982;13:601-9.
24. Mix M, Nitzsche EU. PISAC. A post-injection method for segmented attenuation correction in whole body PET. J Nucl Med 1999;40:297P [abstract].
25. Weiss C. Basiswissen Medizinische Statistik, 2nd edn. Berlin Heidelberg New York: Springer; 2001:249-51.
26. Imdahl A, Jenkner S, Brink I, et al. Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions. Eur J Cardiothorac Surg 2001;20:324-9.
27. Boland GW, Goldberg MA, Lee MJ, et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;194:131-4.
28. 18F-fluorodeoxyglucose positron emission tomography. Am J Roentgenol 1997;168:1357-60.
29. Schumacher T, Brink I, Moser E, et al. Imaging of an adrenal cortex carcinoma and its metastasis with FDG-PET. Nuklearmedizin 1999;38:124-6.
30. Bury T, Barreto A, Daenen F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244-7.
31. Cook GJ, Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer 2000; 88:2927-33.
32. Coleman RE. PET in lung cancer staging. Q J Nucl Med 2001;45:231-4.
33. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432-45.